Axxcess Wealth Management LLC Has $3.88 Million Holdings in Pfizer Inc. $PFE

Axxcess Wealth Management LLC cut its holdings in Pfizer Inc. (NYSE:PFE) by 1.7% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 160,218 shares of the biopharmaceutical company’s stock after selling 2,808 shares during the quarter. Axxcess Wealth Management LLC’s holdings in Pfizer were worth $3,884,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. GKV Capital Management Co. Inc. acquired a new stake in Pfizer in the first quarter valued at about $27,000. Bayforest Capital Ltd bought a new position in Pfizer in the first quarter valued at about $28,000. North Capital Inc. bought a new position in Pfizer in the first quarter valued at about $28,000. WPG Advisers LLC bought a new position in Pfizer in the first quarter valued at about $35,000. Finally, Horizon Financial Services LLC bought a new position in Pfizer in the first quarter valued at about $35,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have commented on PFE. Citigroup increased their target price on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. UBS Group reiterated a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a research report on Wednesday, October 1st. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Bank of America increased their target price on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus target price of $28.35.

Pfizer Price Performance

Shares of PFE opened at $24.53 on Wednesday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $29.82. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The company has a market capitalization of $139.44 billion, a price-to-earnings ratio of 13.05, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. The business has a 50-day moving average of $24.88 and a 200-day moving average of $24.12.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer’s payout ratio is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.